PDS Enterprise Value Over E B I T D A from 2010 to 2024

PDSB Stock  USD 2.15  0.04  1.90%   
PDS Biotechnology's Enterprise Value Over EBITDA is increasing over the years with slightly volatile fluctuation. Enterprise Value Over EBITDA is expected to dwindle to -3.17. From 2010 to 2024 PDS Biotechnology Enterprise Value Over EBITDA quarterly data regression line had arithmetic mean of (8.95) and significance of  0. View All Fundamentals
 
Enterprise Value Over EBITDA  
First Reported
2010-12-31
Previous Quarter
(3.02)
Current Value
(3.17)
Quarterly Volatility
10.5685143
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check PDS Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PDS Biotechnology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 54.5 K, Interest Expense of 4.4 M or Selling General Administrative of 11.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 6.18. PDS financial statements analysis is a perfect complement when working with PDS Biotechnology Valuation or Volatility modules.
  
Check out the analysis of PDS Biotechnology Correlation against competitors.

Latest PDS Biotechnology's Enterprise Value Over E B I T D A Growth Pattern

Below is the plot of the Enterprise Value Over E B I T D A of PDS Biotechnology Corp over the last few years. It is PDS Biotechnology's Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in PDS Biotechnology's overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Over E B I T D A10 Years Trend
Slightly volatile
   Enterprise Value Over E B I T D A   
       Timeline  

PDS Enterprise Value Over E B I T D A Regression Statistics

Arithmetic Mean(8.95)
Coefficient Of Variation(118.03)
Mean Deviation8.63
Median(6.73)
Standard Deviation10.57
Sample Variance111.69
Range31.3057
R-Value0.72
Mean Square Error57.87
R-Squared0.52
Significance0
Slope1.70
Total Sum of Squares1,564

PDS Enterprise Value Over E B I T D A History

2024 -3.17
2023 -3.02
2022 -7.86
2021 -6.73
2020 -0.52
2019 -0.1
2018 6.87

About PDS Biotechnology Financial Statements

PDS Biotechnology stakeholders use historical fundamental indicators, such as PDS Biotechnology's Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although PDS Biotechnology investors may analyze each financial statement separately, they are all interrelated. For example, changes in PDS Biotechnology's assets and liabilities are reflected in the revenues and expenses on PDS Biotechnology's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in PDS Biotechnology Corp. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Enterprise Value Over EBITDA(3.02)(3.17)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether PDS Biotechnology Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PDS Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pds Biotechnology Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pds Biotechnology Corp Stock:
Check out the analysis of PDS Biotechnology Correlation against competitors.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PDS Biotechnology. If investors know PDS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PDS Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.17)
Return On Assets
(0.40)
Return On Equity
(1.28)
The market value of PDS Biotechnology Corp is measured differently than its book value, which is the value of PDS that is recorded on the company's balance sheet. Investors also form their own opinion of PDS Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is PDS Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PDS Biotechnology's market value can be influenced by many factors that don't directly affect PDS Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PDS Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if PDS Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PDS Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.